INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of BELLUS Health Inc. (BLU) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of BELLUS Health Inc. (“BELLUS” or the “Company”) (NASDAQ: BLU) investors concerning the Company’s possible violations of federal securities laws.

BELLUS is a clinical-stage biopharmaceutical company whose lead product is BLU-5937, which is being developed for the treatment of chronic cough and other afferent hypersensitization-related disorders.

On July 6, 2020, before the market opened, BELLUS announced topline results from its Phase 2 RELIEF trial of BLUE-5937 in patients with refractory chronic cough. According to the Company, the trial “did not achieve statistical significance for the primary endpoint of reduction in placebo-adjusted cough frequency at any dose tested.”

On this news, the Company’s stock price fell $9.05, or 75%, over two consecutive trading sessions to close at $2.97 on July 8, 2020, thereby injuring investors.

If you purchased BELLUS securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at [phone], toll-free at [phone], or by email to [e-mail], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.